Development and Validation of a Method for the Quantitative Determination of Etoricoxib in Liquid Dosage Form

Introduction. Etoricoxib is a selective cyclooxygenase (COX-2) inhibitor used for the treatment of acute pain and has anti-inflammatory analgesic efficacy. causes fewer complications compared to other non-steroidal drugs (NSAIDs). FSI "SID GP" developed an ophthalmic liquid dosage form based on etoricoxib. This article proposes method determining content etoricoxib in by high performance chromatography with UV detection. Aim. Development validation quantitative determination form. Materials methods. Eye drops concentration active substance 0.05 % were analysis, standard sample (Kekule Pharma Limited, India, series ACE-3 WS001/15). Chromatographic separation performed Agilent 1220 Infinity II LC chromatograph (Agilent Technologies, USA) equipped gradient pump, column thermostat, diode array detector. The analysis carried out Kromasil C8 250 × 4.6 mm, using acetonitrile M buffer solution potassium dihydrogen phosphate pH = 4.2 as mobile phase ratio 46 : 54. time was 15 minutes at detection wavelength 235 nm. Results discussion. A validated according following indicators: specificity, linearity, accuracy, range, intermediate precision, repeatability. Conclusion. According results tests, all listed parameters meet acceptance criteria. proposed characterize efficiency specificity.